|
Feb 19
|
|
$379.73
$379.73
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
End of Apogee (APGE) Drug Collaboration Leads...
|
|
Feb 19
|
|
$379.73
$379.73
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Amgen Details Oncology R&D Push, IMDELLTRA Ex...
|
|
Feb 18
|
|
$379.73
$379.73
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Amgen Inc. (AMGN) Presents at Citi's 2026 Vir...
|
|
Feb 18
|
|
$379.73
$379.73
+0.0%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Piper Sandler Maintains Overweight on Amgen, ...
|
|
Feb 17
|
|
$373.36
$379.73
+1.7%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
MATTERWORKS, INC. ANNOUNCES UPDATE TO LEADERS...
|
|
Feb 14
|
|
$369.19
$379.73
+2.9%
|
NEUTRAL
|
Finnhub News
|
The headline questions whether UPLIZNA's EU approval will reshape Amgen's rare disease strategy and investment outlook. |
Finnhub - AMGN
Is UPLIZNA’s EU Approval Reframing Amgen’s Ra...
|
|
Feb 14
|
|
$369.19
$379.73
+2.9%
|
LONG
|
Finnhub News
|
InflaRx highlighted positive Izicopan HS data, outlined Phase 2b plans, and announced significant cost reductions at a summit. |
Finnhub - AMGN
InflaRx Spotlights Izicopan HS Data, Phase 2b...
|
|
Feb 13
|
|
$369.19
$379.73
+2.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOL...
|
|
Feb 13
|
|
$369.19
$379.73
+2.9%
|
NEUTRAL
|
Finnhub News
|
Amgen has filed for a mixed shelf offering, allowing it to issue various securities in the future, though the specific size was not revealed. |
Finnhub - AMGN
Amgen Files For Mixed Shelf Offering; Size No...
|
|
Feb 13
|
|
$369.19
$379.73
+2.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Here’s What Argus Research and Guggenheim Are...
|
|
Feb 13
|
|
$369.19
$379.73
+2.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Prices, pipelines and patent cliffs: Inside p...
|
|
Feb 13
|
|
$369.19
$379.73
+2.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
1 Large-Cap Stock Worth Your Attention and 2 ...
|
|
Feb 13
|
|
$369.19
$379.73
+2.9%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Amgen Conference: UPLIZNA Phase III Plans, Da...
|
|
Feb 12
|
|
$363.68
$379.73
+4.4%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Amgen Inc. (AMGN) Presents at Piper Sandler V...
|
|
Feb 12
|
|
$363.68
$379.73
+4.4%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Amgen (NASDAQ:AMGN) Is Increasing Its Dividen...
|
|
Feb 12
|
|
$363.68
$379.73
+4.4%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Upstream Bio’s stock drops 47% on verekitug P...
|
|
Feb 11
|
|
$364.06
$379.73
+4.3%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Asthma Drugs Market to Reach USD 41.18 Billio...
|
|
Feb 11
|
|
$364.06
$379.73
+4.3%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Upstream Bio Crashes After Asthma Drug Succee...
|
|
Feb 11
|
|
$364.06
$379.73
+4.3%
|
N/A
|
Finnhub News
|
— |
Finnhub - AMGN
Review & Preview: Consumers Show Strain
|